Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC2A1 | P11166 | 2/20 | 0.34 |
| ▸ | GCGR | P47871 | 6/20 | 0.33 |
| ▸ | SCN8A | Q9UQD0 | 1/20 | 0.32 |
| ▸ | AVPR1B | P47901 | 1/20 | 0.32 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.31 |
| ▸ | PPARD | Q03181 | 1/20 | 0.31 |
| ▸ | PPARA | Q07869 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5119291 | 0.92 | SLC2A1 (0.37) | SLC2A1ALDH1A1 | |
| SCHEMBL5114290 | 0.88 | BDKRB1 (0.35) | GCGREPHX2 | |
| SCHEMBL5118264 | 0.86 | SLC2A1 (0.35) | SLC2A1AVPR1BEPHX2ALDH1A1 | |
| SCHEMBL5114099 | 0.84 | SLC2A1 (0.37) | SLC2A1ALDH1A1RAB9A | |
| SCHEMBL5119728 | 0.82 | LMNA (0.31) | — | |
| SCHEMBL5125538 | 0.81 | BDKRB1 (0.38) | SLC2A1ALDH1A1 | |
| SCHEMBL5126502 | 0.79 | KMT2A (0.34) | EPHX2ALDH1A1 | |
| SCHEMBL5118850 | 0.79 | LMNA (0.42) | — | |
| SCHEMBL5125825 | 0.79 | MEN1 (0.35) | SLC2A1ALDH1A1 | |
| SCHEMBL5119282 | 0.79 | BDKRB1 (0.42) | SLC2A1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7361687-B2 | Arylsulphonamide derivatives and methods of preparing | LABORATOIRES FOURNIER SA (FR) | 2008-04-22 | — | — | US | disclosed |
| US-20060084699-A1 | Novel arylsulphonamide derivatives and use thereof as therapeutic agents | LABORATOIRES FOURNIER SA (FR) | 2006-04-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060084699-A1 | Novel arylsulphonamide derivatives and use thereof as therapeutic agents | UGT1A1, UGT2B7, UGT1A6 | SLC2A1 2323/4885GCGR 1878/4885SCN8A 3739/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.